Effects of aging on protein expression in mice brain microvessels: ROS scavengers, mRNA/protein stability, glycolytic enzymes, mitochondrial complexes, and basement membrane components

Partha K. Chandra · Sinisa Cikic · Ibolya Rutkai · Jessie J. Guidry · Prasad V. G. Katakam · Ricardo Mostany · David W. Busija

Received: 30 July 2021 / Accepted: 23 September 2021 / Published online: 28 October 2021
© The Author(s) 2021

Abstract Differentially expressed (DE) proteins in the cortical microvessels (MVs) of young, middle-aged, and old male and female mice were evaluated using discovery-based proteomics analysis (>4,200 quantified proteins/group). Most DE proteins (>90%) showed no significant differences between the sexes; however, some significant DE proteins showing sexual differences in MVs decreased from young (8.3%), to middle-aged (3.7%), to old (0.5%) mice. Therefore, we combined male and female data for age-dependent comparisons but noted sex differences for examination. Key proteins involved in the oxidative stress response, mRNA or protein stability, basement membrane (BM) composition, aerobic glycolysis, and mitochondrial function were significantly altered with aging. Relative abundance of superoxide dismutase-1/-2, catalase and thioredoxin were reduced with aging. Proteins participating in either mRNA degradation or pre-mRNA splicing were significantly increased in old mice MVs, whereas protein stabilizing proteins decreased. Glycolytic proteins were not affected in middle age, but the relative abundance of these proteins decreased in MVs of old mice. Although most of the 41 examined proteins composing mitochondrial complexes I–V were reduced in old mice, six of these proteins showed a significant reduction in middle-aged mice, but the relative abundance increased in fourteen proteins. Nidogen, collagen, and laminin family members as well as perlecan showed differing patterns during aging, indicating BM reorganization starting in middle age. We suggest that increased oxidative stress during aging leads to adverse protein profile changes of brain cortical MVs that affect mRNA/protein stability, BM integrity, and ATP synthesis capacity.

Keywords Cortical microvessels · Proteomics · Brain aging · ROS scavengers · mRNA/protein stability · Glycolytic/mitochondrial proteins
Introduction

Cerebral microvessels (MV: end arterioles, capillaries, and venules) are essential for maintenance of nutrient supply for brain metabolic needs while ensuring immunological and physical sequestration of brain tissues from harmful circulating substances via the blood–brain barrier (BBB) and basement membrane (BM) [1]. MVs are also the most vulnerable-to-stress segments of the brain vasculature. They must maintain high ATP production rates via glycolysis and oxidative phosphorylation (OXPHOS), essential for a variety of functions: the regulation of capillary perfusion pressure, transport across the BBB, BM maintenance, and tight nutrient delivery/brain metabolism coupling. They are also subject to exposure from potentially disruptive or toxic agents released from neurons or circulating blood. Aging is an unavoidable stress with an ever-increasing detrimental effect on the brain microvasculature, which affects neuronal health and function and adds vulnerability to strokes and dementias, such as Alzheimer’s disease (AD). Gross anatomical age-related changes also are reported: decreases in small blood vessel [2] and capillary density [3–5], looping, tortuosity, and twisting [6–11] of MVs, and reorganization and BBB leakage. Unfortunately, the role of different proteins in cortical MVs in the etiology of aging and development of neurological diseases has received little attention due to a prior focus on large arteries and because of methodological challenges in interpreting the complexity of factors involved in the synthesis and stability of proteins and protein interactions.

Recently, we reported on our proteomics approaches to examine expression and interactions of large numbers of proteins in MVs in young male and female rodents, with an emphasis on mitochondrial and related proteins [12, 13]. In the current study, we have expanded our investigation and have performed a more extensive examination of proteins involved in the structure and function of MVs using a discovery-based quantitative proteomics approach quantifying more than 4200 differentially expressed (DE) proteins/group in cortical MVs of young, middle-aged, and old male and female mice. Specifically, we focused on proteins involved in BM formation, ROS scavenging, mRNA/protein stability maintenance, and ATP production via glycolysis and OXPHOS.

Materials and methods

Animals

Age-matched, male and female, young (4–6 months), middle-aged (12–14 months), and old (20–21 months) mice were included in this study. Mice were obtained from Jackson Laboratory [Tg(Thy1-EGFP)Mirs/J] (Jax No. 007788) and bred in a C57B16J background. Sample sizes included 3 male and 3 female MVs per age group. Mice were kept in group housing at ~23 °C on a 12-h light/dark cycle with ad libitum access to food and water. This study conforms to the Institutional Animal Care and Use Committee guidelines of Tulane University, the National Institutes of Health Office of Laboratory Animal Welfare guidelines, and the ARRIVE guidelines for animal research. All MVs were collected at the same time of day to avoid any differences due to circadian rhythm.

Microvessels isolation

The MVs were isolated as previously described [12, 13]. Large, superficial, blood-vessel-free, cortical tissue from mice brains was homogenized in ice cold Dulbecco’s phosphate-buffered saline (DPBS) (Life Technologies Corporation, NY, USA) and centrifuged at 3300 × g for 15 min. The pellet was resuspended in 17.5% dextran (Thermo Fisher Scientific, Waltham, MA) and passed through a 300-µm filter (pluriSelect Life Science, CA, USA). The filtrate was centrifuged at 7900 × g for 15 min. The contaminated myelin was eliminated, and the MV pellet was resuspended in 2% bovine serum albumin (BSA) (Sigma-Aldrich, St Louis, MO) and passed through a 70-µm filter (Corning Incorporated, NY, USA). To achieve impurity-free MVs, the subsequent sample was centrifuged at 13,000 × g for 15 min with a final clean-up with dextran (17.5%) followed by BSA (2%). Last, the MV pellet was resuspended in 2% bovine serum albumin (BSA) (Sigma-Aldrich, St Louis, MO) and passed through a 70-µm filter (Corning Incorporated, NY, USA). To achieve impurity-free MVs, the subsequent sample was centrifuged at 13,000 × g for 15 min with a final clean-up with dextran (17.5%) followed by BSA (2%). Last, the MV pellet was resuspended in DPBS and stored at −80 °C until used. The MV preparation integrity has been validated as described in our studies [12–15].

Quantitative discovery-based proteomics using tandem mass tags (TMT) and liquid chromatography mass spectrometry (LC–MS)

Samples were prepared for discovery-based quantitative proteomic analysis by the addition of 1% SDS
and sonicated until completely homogenous. The protein concentration was determined using BCA protein assay kit (Pierce, Thermo Scientific) and an eight-point standard curve. Based on the protein concentration, 100 µg of each protein sample was prepared for trypsin digestion by reducing the cysteines with tris(2-carboxyethyl)phosphine followed by alkylation with iodoacetamide. After chloroform–methanol precipitation, each protein pellet was digested with 1 µg trypsin overnight at 37 °C. Tryptic peptides were labeled using one of three TMT 6-plex reagents sets (Thermo Scientific Pierce); old, middle, and young.

An equal amount of each TMT-labeled sample was pooled in a single tube with SepPak purified (Waters, Ireland) using acidic reverse phase conditions. We used off-line fractionation to reduce the sample complexity, as previously described [12, 13]. The fractionated, labeled peptide mixtures were run on a Dionex U3000 nano-flow system coupled to a Thermo Fisher Fusion Orbitrap mass spectrometer. Each fraction was subjected to a 95-min chromatographic method employing a gradient from 2 to 25% ACN in 0.1% formic acid (FA) (ACN/FA) over the course of 65 min, a gradient of 50% ACN/FA for an additional 10 min, and then 90% ACN/FA for 5 min, with a 15-min re-equilibration into 2% ACN/FA. Chromatography was carried out in a “trap-and-load” format using an EASY-Spray source (Thermo); trap column C18 PepMap 100, 5 µm, 100 A, and the separation column was an EASY-Spray PepMap RSLC C18 2 µm, 100 A, 75 µm x 25 cm (Thermo Fisher Dionex, Sunnyvale, CA). The entire run had a flow rate of 0.3 µL/min. Electrospray was achieved at 1.8 kV.

We used an MS3 approach for TMT data acquisition, as previously described [16]. Survey scans (MS1) were performed in the Orbitrap using 120,000 resolutions. Data-dependent MS2 scans in the linear ion trap used a collision-induced dissociation (CID) of 25%. Reporter ions were fragmented using a high-energy collision dissociation (HCD) of 55% and detected in the Orbitrap at 50,000 resolutions (MS3). This was repeated for three technical replicates. The 3 runs of each age group were searched using the SEQUEST HT node of Proteome Discoverer 2.4 (Thermo). The Protein FASTA database was the Mus musculus, SwissProt tax ID = 10,090, version 2017–10-25 containing 25,097 sequences. Static modifications included TMT reagents on lysine and N-terminus (+229.163); carbamidomethyl on cysteines (+57.021); dynamic phosphorylation of serine, threonine, and tyrosine (+79.966 Da); and dynamic modification of oxidation of methionine (+15.9949). Parent ion tolerance was 10 ppm, fragment mass tolerance was 0.6 Da for MS2 scans, and the maximum number of missed cleavages was set to 2.

Statistical analysis

Only high scoring peptides were considered using a false discovery rate of <1%, and only one unique high-scoring peptide was required for inclusion of an identified protein in our results. Proteome Discoverer was also used to determine quantitative differences between biological groups. We used a t test analysis for quantitative data by grouping biological replicates and performing pair-wise comparisons for fold change: old, middle-aged, and young mice. The normalized abundance quantity of a biological replicate was calculated from an average of three experimental replicates. The data was presented as mean ± standard deviation (SD). Initially, the data sets were assessed by the Shapiro–Wilk test for normality followed by unpaired t test with Welch correction for normally distributed data. When the data did not pass the normality test, a non-parametric Mann–Whitney test was performed as indicated in the figure legends. The statistical analysis was performed using GraphPad Prism version 9.0.0 for Windows, and p <0.05 was considered statistically significant.

Results

Age- and sex-specific quantification of DE proteins in cortical MVs of mice

More than 4200 DE proteins were quantified in cortical MVs of young, middle-aged, and old mice. The number of significant sex-dependent DE proteins (abundance ratio: female/male) in cortical MVs generally decreased from young (8.3%), middle-aged (3.7%), to old (0.5%) mice (Supplementary Table 1). Due to the notable (>90%) lack of significant sex differences, especially in old mice MVs, we combined male and female data to strengthen the statistical
analyses. When sex differences were more prominent and important to consider, we note this information in the text and include details in Supplementary Materials.

Oxidative stress response proteins were altered with aging in mice cortical MVs

The expressions of superoxide dismutase 1 (SOD1) and superoxide dismutase 2 (SOD2) were significantly decreased in aged compared with young and middle-aged mice (Fig. 1A–B). Moreover, the expressions of catalase (CAT) and thioredoxin (TXN1) were significantly decreased both in middle-aged and old mice MVs (Fig. 1C–D). While glutathione synthase (GSS) and glutathione peroxidase-1 (GPX1) levels were not significantly reduced during aging (Fig. 1E–F), the enzymes involved in the glutathione cycle were significantly differentially expressed in MVs of young, middle-aged, and old mice. For example, glutathione hydrolase 1 proenzyme (GGT1)-expression in old mice MVs was significantly decreased compared with middle-aged or young mice (Fig. 1G). Interestingly, the expression of glutathione S transferase kappa 1 (GSTK1) was significantly decreased, but glutathione hydrolase 7-expression was increased in middle-aged MVs (Fig. 1H–I). Remarkably, glutathione reductase-expression was significantly higher in old compared with young mice MVs (Fig. 1J).

Proteins involved in mRNA/protein stability changed during aging

Proteins involved in either mRNA stability (polyadenylate-binding protein 1: PABPC1) or proper protein folding (mitochondrial 60 and 70 kDa heat shock proteins: HSPA9 and HSPD1, respectively) were more decreased in middle-aged and old cortical MVs than young MVs (Fig. 2A–C). Alternatively, non-canonical poly(A) RNA polymerase PAPD5 (Papd5), 5’-3’ exoribonuclease 2 (XRN2), and superkiller viralicidic activity 2-like 2 (SKIV2L2) which are involved in either mRNA degradation or pre-mRNA splicing were significantly upregulated in MVs of old compared with middle-aged and young mice (Fig. 2D–F). The expression of U6 snRNA-associated Sm-like protein LSM7 (LSM7), which plays an important role in pre-mRNA splicing, was significantly decreased in middle-aged and old mice MVs (Fig. 2G–H).

Fig. 1 Decreased expression of oxidative stress response proteins with aging in mouse cortical MVs (panels A–J). Relative protein abundance quantified by TMT-based LC–MS study. Proteins that exhibited group differences are shown as bar graphs with red, green, and blue for young, middle-aged, and old mice, respectively. Graphs show mean ± SD of relative abundance, with between group significant differences indicated by asterisks. NS: not significant. All protein data sets passed the Shapiro–Wilk normality test, and unpaired t test with Welch correction. Age-matched, three males and three females were included in each group (n = 6/group). Sod1 (SOD1), superoxide dismutase 1; Sod2 (SOD2), superoxide dismutase 2; Cat (CAT), catalase; Txn1 (TXN1), thioredoxin; Gss (GSS), glutathione synthetase; Gpx1 (GPX1), glutathione peroxidase 1; Ggt1 (GGT1), glutathione hydrolase 1 proenzyme; Gstk1 (GSTK1), glutathione S-transferase kappa 1; Ggt7 (GGT7), glutathione hydrolase 7; Gsr (GSR), glutathione reductase
role in pre-mRNA splicing via spliceosome, was also increased in middle-aged and old mice MVs (Fig. 2G).

Glycolytic enzymes were significantly decreased with aging in mice

Aging led to reductions in almost all enzyme levels involved in glycolysis in old compared with young and middle-aged mice, including hexokinase-1 (Fig. 3A), glucose-6-phosphate isomerase (Fig. 3B), phosphofructokinase 1 (Fig. 3C), aldolase A (Fig. 3D), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Fig. 3F), phosphoglycerate kinase 1 (Fig. 3G), phosphoglycerate mutase 1 (PGAM1) (Fig. 3H), enolase alpha (Fig. 3I), and pyruvate kinase (Fig. 3J). Only triosephosphate isomerase (TPI) (Fig. 3E) was not significantly reduced in old mice. The expression of glycolytic proteins was similar between males and females for all age groups except for GAPDH and PGAM1 in young mice (Supplementary Fig. 1).

OXPHOS proteins were affected by age

More than 800 mitochondrial and related DE proteins in cortical MVs of young, middle-aged, and old mice were quantified. The number of sex-dependent significant mitochondria-related DE proteins (abundance ratio: female/male) in cortical MVs gradually decreased from young (6.5%: 58/885) to middle-aged (4.4%: 36/816) to old mice (0.7%: 6/830) (Supplementary Table 2). Data point proximity in each graph for complexes I–V support our male and female data grouping; details of sex differences are presented in Supplementary Figures.

The overall aging effect shows widespread decreases in old compared with young and middle-aged mice MVs in all five complexes (6/9 for complex I, 1/3 for complex II, 6/7 for complex III, 8/9 for complex IV, and 10/13 for complex V) (Figs. 4, 5, and 6). A surprising aspect of OXPHOS protein expression is that middle-aged mice often showed a significant increase in specific proteins compared with young mice before these decreased in old mice. We see this...
Fig. 3 Decreased expression of glycolytic enzymes in mouse cortical MVs with aging (panels A–J). Proteomics of glycolysis and associated pathways. Stepwise intermediate products are highlighted in brown, and the pathway is indicated by blue arrows. The abundant expression of enzymes involved in each step is presented in panels A to J. The enzymes that exhibited between group differences are shown as bar graphs with red, green, and blue for young, middle-aged, and old mice, respectively. Graphs show mean ± SD of relative abundance, with significant differences between groups indicated by asterisks. The protein abundance in MVs of old mice is presented in panels (A), (B), (C), (E), (G), (H), and (J). These panels did not pass the Shapiro–Wilk normality test, and the non-parametric Mann–Whitney test was used. Proteins in panels (D), (F), and (I) passed the Shapiro–Wilk normality test and were followed by unpaired t test with Welch correction. Age-matched, three males and three females were included in each group (n=6/group). G-6-P Isomerase, glucose-6-phosphate isomerase; Triose-P-isomerase, triosephosphate isomerase; Gly-3-p-Dehy- drogenase, glyceraldehyde 3-phosphate dehydrogenase; P-glycerate kinase 1, phosphoglycerate kinase 1; P-glycerate mutase 1, phosphoglycerate mutase 1.

pattern with ND2 and NDUFS1 in complex I (Fig. 4B and D); SDHA in complex II (Fig. 4E); UQCRFS1 and UQCRH in complex III (Fig. 4F and G); COX2, COX5a, and COX5b in complex IV (Fig. 5A–B); and ATP5B, ATP5C1, ATP5F1, and ATP5H in complex V (Fig. 6A, B, and D). However, in some cases, mitochondrial proteins in MVs decreased in middle age compared with young mice: NDUFV2 in complex I (Fig. 4C), 1/9; none for complex II (Fig. 4); UQCR10 in young female and UQCRB in middle-aged female were significantly less expressed than male (Supplementary Fig. 4A–B). Similarly, in complex IV, the expression of COX4I1 and COX6C in young female, COX2 and COX5A in middle-aged female, and COX7C in old female was significantly less than in male (Supplementary Fig. 5A–C). In complex V, the expression of ATP5C1 was significantly decreased in both young and middle-aged female mice. Interestingly, the relative abundance of ATP5J was significantly higher in young female but was decreased significantly in old female MVs (Supplementary Fig. 6A–C).

Although the OXPHOS proteins largely show parity between the sexes, the expression of other mitochondrial-related proteins shows a more complex pattern (data not presented). For example, proteins...
involved in mitochondrial transcription/translation are heavily slanted to males in young mice, and proteins involved in fatty acid metabolism are more abundantly expressed in female compared with male mice in middle age. The other mitochondrial-related proteins are equally expressed in male and females in old mice.

Basement membrane proteins were affected by age

Basement membranes are composed of many structurally different components, and the composition of BMs varies according to anatomical location.

Involved in mitochondrial transcription/translation are heavily slanted to males in young mice, and proteins involved in fatty acid metabolism are more abundantly expressed in female compared with male mice in middle age. The other mitochondrial-related proteins are equally expressed in male and females in old mice.

Basement membrane proteins were affected by age

Basement membranes are composed of many structurally different components, and the composition of BMs varies according to anatomical location.

For cortical MVs, the BM is composed of nidogen, collagen, and laminin components and perlecan (HSPG2) (Fig. 7). While a modest decrease in old mice compared with young mice occurred with NID1, expression of NID2 did not change (Fig. 7A). The collagen proteins showed a complex pattern which differed among the subtypes. The expression of COL4A1, COL6A1, and COL4A2 showed a progress decrease in middle-aged and old mice, whereas COL1A1, COL6A2, COL12A1, COL15A1, and COL18A1 showed increases either/and in middle-aged and old age compared with young mice (Fig. 7B–D). Laminin subtypes

Fig. 4 Altered age-specific expression of mitochondrial complexes I, II, and III proteins in mouse cortical MVs (panels A–G). Abundant expression of different proteins involved in mitochondrial complex I (A–D), complex II (E), and complex III (F–G) that exhibited differences between groups are shown as bar graphs. Graphs show mean ± SD of relative abundance, with significant differences between groups presented as indicated. Proteins presented in different panels passed the Shapiro–Wilk normality test followed by unpaired t test with Welch correction. Age-matched, three males and three females were included in each group (n=6/group). ND1, NADH-ubiquinone oxidoreductase chain 1; ND2, NADH-ubiquinone oxidoreductase chain 2; ND4, NADH-ubiquinone oxidoreductase chain 4; ND5, NADH-ubiquinone oxidoreductase chain 5; Ndufv1 (NDUFV1), NADH dehydrogenase [ubiquinone] flavoprotein 1; Ndufv2 (NDUFV2), NADH dehydrogenase [ubiquinone] flavoprotein 2; Ndufs1 (NDUFS1), NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial; Ndufs2 (NDUFS2), NADH dehydrogenase [ubiquinone] iron-sulfur protein 2; Ndufs3 (NDUFS3), NADH dehydrogenase [ubiquinone] iron-sulfur protein 3; Sdha (SDHA), succinate dehydrogenase [ubiquinone] flavoprotein subunit; Sdhb (SDHB), succinate dehydrogenase [ubiquinone] iron-sulfur subunit; Sdhc (SDHC), succinate dehydrogenase cytochrome b560 subunit; Uqcrb (UQCRB), cytochrome b-c1 complex subunit 7; Uqcr1 (UQCR1), cytochrome b-c1 complex subunit 1; Uqcr2 (UQCR2), cytochrome b-c1 complex subunit 2; Uqcrfs1 (UQCRFS1), cytochrome b-c1 complex subunit Riske; Uqcrh (UQCRH), cytochrome b-c1 complex subunit 6; Uqcrq (UQCRQ), cytochrome b-c1 complex subunit 8; Uqcr10 (UQCR10), cytochrome b-c1 complex subunit 9

For cortical MVs, the BM is composed of nidogen, collagen, and laminin components and perlecan (HSPG2) (Fig. 7). While a modest decrease in old mice compared with young mice occurred with NID1, expression of NID2 did not change (Fig. 7A). The collagen proteins showed a complex pattern which differed among the subtypes. The expression of COL4A1, COL6A1, and COL4A2 showed a progress decrease in middle-aged and old mice, whereas COL1A1, COL6A2, COL12A1, COL15A1, and COL18A1 showed increases either/and in middle-aged and old age compared with young mice (Fig. 7B–D). Laminin subtypes

© Springer
also showed a mixed response (Fig. 7E–F). Only LAMA5 and LAMB1 showed a reduction in middle-aged compared with young mice, whereas LAMA1 increased and LAMA2 decreased in old compared with middle-aged mice. For perlecan, a decrease in expression was seen in old compared with middle-aged mice (Fig. 7F).

**Discussion**

The major finding of this study is that significant changes occur in the protein composition of brain MVs of old mice, which increases the vulnerability of this cerebral vascular segment to ongoing damage and dysfunction, negatively affects cognition, and increases susceptibility to brain injury and disease. First, proteins regulating mRNA/protein stability are deranged starting in mid-life and continuing to old age. Thus, the length of time that intact mRNAs are available for translation is reduced, which leads to decreased protein synthesis, and those proteins that are synthesized will have a reduced lifespan in their original form. Second, important ROS scavenger levels are reduced with aging, corresponding with reports of increased ROS availability in old age. Third, enzyme levels involved in glycolysis and many components of mitochondrial complexes I–V are reduced, which will decrease the ability of MVs to provide the necessary ATP response to stress and injury. Fourth, the BM components undergo aging changes, which may lead to inappropriate alterations in MV structural integrity. We propose that reduced ROS scavenging ability coupled with subsequent increased oxidative damage and mRNA/protein stability are early, precipitating events leading to energy failure and BM disruption (Fig. 8—schematic). In addition, the results indicate that detrimental effects of normal aging occur as early as 12–14 months in mice and thus provide support for the view that therapies, especially in vulnerable individuals, should begin in mid-life.

**ROS scavenger proteins during aging**

A dominant theory in the aging literature focuses on the accumulation of damaging effects of ROS on cells which could arise via enhanced ROS production, decreased antioxidant systems, or a combination of both [17, 18]. Using two photon microscopies, Han et al. [19] detected increased levels of ROS in the cerebral vessels of old mice. However, despite overwhelming evidence supporting the idea that ROS are produced and can manifest damage in cells, a causal link between ROS and normal aging has not been clearly established. Mitochondria are major source of ROS in aging brain, but other important contributors include enzymes within the plasma membrane, NADPH oxidases (NOXs), lipid metabolism, and various cytosolic enzymes such as cyclooxygenases. In the vasculature, NOX enzymes are a substantial source of ROS, and are key players in mediating redox signaling under physiological and pathophysiological conditions including age-associated diseases.
However, the contribution of NOX enzymes as a source of oxidant stress during normal aging process has not been clearly established. While we did not measure ROS production or the source of ROS in MVs, we intend to do so in future studies. Nonetheless, reduced ROS scavenging systems during aging compromise the brain microvasculature. There are studies supporting the concept that a decrease in antioxidant defenses appears with aging [27–29] which support our findings. Postmortem studies of different human brain regions uncovered a gradual age-related decrease in SOD and CAT as well as GSH reductase activity, mainly in the hippocampus and frontal cortex [30]. In line with these observations, in vivo monitoring of GSH content in the human brain from healthy subjects exhibited a steady decrease in this antioxidant enzyme in old compared with young individuals [29]. Studies in old rat brains revealed a decrease in SOD2 activity compared with young rat brains [31].

In this regard, we found that the relative abundances of SOD1, SOD2, CAT, and TXN1 were significantly decreased in cortical MVs of old mice (Fig. 1A–D). The decrease in the relative abundance of CAT and TXN1 in middle age indicates that the potential for increased oxidative stress becomes manifest relatively early in mice MVs. In addition to the primary antioxidants, many secondary antioxidants such as GPX1 form redox cycles that offer necessary cofactors for primary antioxidants and can also function as direct scavengers of ROS [32–35]. Although the expression of GSS and GPX1 was not decreased with aging, the redox cycle proteins such as GGT1 and GSTK1 were also significantly decreased in old mice MVs (Fig. 1E–H). These enzymatic and nonenzymatic
Antioxidant systems are essential to ensure the health of cells by maintaining the optimal redox balance as well as decrease or avoid cellular damage caused by ROS [36–38].

mRNA/protein stability during aging

Messenger RNA turnover mechanisms regulate the lifetime of cytoplasmic mRNAs as a means of controlling gene expression under both normal and stress conditions, whereas the impact of mRNA turnover on aging and age-related disorders has recently become apparent [39]. Age-dependent changes in mRNA decay are currently unknown; however, some mechanistic pathways are beginning to emerge [40]. Several age-related neurodegenerative disorders are associated with deficiencies in RNA-binding protein function and play regulatory roles in longevity [41–44]. Many proteins, including cytoplasmic poly(A)-binding protein 1 (PABPC1), bind the poly(A) tail of mRNA, including that of its own transcript, and regulate mRNA metabolism processes and mRNA stability [45–47]. We observed that PABPC1 expression was significantly decreased in cortical MVs with aging (Fig. 2A).

On the other hand, the mRNA processing bodies (also known as P-bodies) are mainly involved in translational repression and mRNA decapping and degradation. The P-body components include the decapping enhancers LSM1–7, and the 5’ to 3’ exonuclease XRN1 or XRN2 that regulate the decapping or degradation rate of mRNAs [48–50]. In the 3’ to 5’ decay pathway, mRNAs are degraded in this direction by the SKI RNA helicase complex [51, 52]. We observed that the expression of PABP5, XRN2, SKIV212, and LSM7 involved in...
the mRNA degradation or pre-mRNA splicing critical for longevity [53, 54] were upregulated in MVs of old mice (Fig. 2D–G). Alternative RNA splicing is accomplished by large ribonucleoprotein complexes, known as spliceosomes. Several RNA binding proteins act as splicing regulators to expedite or inhibit splice site recognition by spliceosome components [55]. A gene ontology analysis in both human and mouse reported that changes in pathways such as mRNA binding, RNA processing, and RNA splicing are strongly associated with age [56, 57]. Age-related splicing fluctuations in the human brain affect pathways such as sugar metabolism and DNA repair [58], both pertinent to aging [59, 60]. Recently, Ubaida-Mohien et al. [61] reported that spliceosomal proteins were increased by ~15% between the ages of 20 and 87 years, and they propose that changes in the splicing machinery enable muscle cells to respond to a rise in damage with human aging. Systematic changes in the splicing machinery with older age were also suggested by epidemiological studies [62], transcriptomic analyses of skeletal muscle biopsies [63, 64], and human peripheral blood leukocytes [57] of young and old individuals. During or after translation, proteins adapt their structures in a process called folding. Generally, folding is accelerated by chaperones and associated protein activity. Decreased chaperone capacity with age has been shown in numerous studies [65–67]. We observed that HSPA9 and HSPD1 were involved in protein folding and were decreased more significantly in MVs of middle-aged and old than in young mice (Fig. 2B–C). The signaling process concerning whether to degrade a protein is affected in part by the availability of ATP in the cell. Decline of cellular energetics with age and disruption of fatty acid and glucose metabolism decreases the amount of available ATP and changes chaperone activity, leading to the accumulation of damaged proteins [68, 69].

Anaerobic glycolysis during aging

Glycolysis is crucial for energy production in the developing brain, whereas OXPHOS becomes more dominant in the mature brain [70]. We are unaware of
any studies which have considered the effects on glycolysis of aging brain cortical MVs. Recently, brain glycolysis has been recognized as a process not only involved in hypoxic conditions, but also as a critical pathway affecting signal transduction, synaptic activity, learning, and brain development [70–73]. In normoxic conditions, glycolysis can promptly increase intracellular ATP levels with the changing demands of a cell for activation, proliferation, secretion, migration, and apoptosis [74–76]. Moreover, the metabolic control of angiogenesis or barrierogenesis may be provided by glycolytic activity of the neurovascular unit cells [77]. The ATP required by neurons [78], and microglia [79] is predominantly generated within mitochondria by OXPHOS. In contrast, energy requirements of astrocytes [80] and oligodendrocytes [81] are predominantly met by glycolysis. In the cerebral vasculature, glycolysis promotes vessel branching [82, 83], and whereas endothelial migration is associated with angiogenic events [82], the suppression of glycolysis results in impairment of angiogenesis [84, 85]. During angiogenesis, the developing capillaries are more permeable than established vessels [86]. However, there appears to be an age-related decrease in the capacity for cerebral angiogenesis [87, 88]. Several vascular density studies in aging rats reported decreases in capillary number, length, volume, and vascular density in hippocampus, cortex, white matter, and brain stem regions [89–96]. Similarly, in human aging, decrease in capillary/vascular density in cortex and other brain areas is also reported in several studies [3–5, 97]. During aging, the human brain experiences normal changes including a global decline in glucose metabolism, oxygen consumption, and cerebral blood flow [71, 98–100]. Recently, Goyal et al. (2017) reported that average aerobic glycolysis gradually decreases with age, approaching zero at the whole-brain level close to the age of 60 [98]. These conclusions are strongly supported by a prior quantitative study in cognitively normal active young and older adults [101]. In healthy aging, brain glucose metabolism decreases mainly in the frontal cortex, whereas in AD and other neurodegenerative diseases, the parietal lobe and precuneus are the most significantly affected [102]. Our present study indicates that except for TPI, the expressions of all other glycolytic enzymes were significantly decreased with aging in mice cortical MVs (Fig. 3). Inhibition of the “house-keeping” glycolytic enzyme, GAPDH, by nitric oxide results in higher BBB permeability and barrier dysfunction [103]; the same effect is provoked by overproduction of ROS in endothelial mitochondria [104]. The aging-related decrease of anaerobic glycolysis may also indicate a loss of neuroprotection against oxidative stress via the pentose phosphate pathway, increasing the risk for oxidative damage. The aging-related loss of glycolysis in the absence of an amyloid or neurologically distinct brain pathology suggests an underlying physiological change that harbors poor outcomes to the aging brain. Decreased anaerobic glycolysis might provide a template for the onset of more severe brain energetic deficits in neurodegenerative diseases [98, 105–108].

Mitochondrial proteins during aging

The mitochondrial theory of aging hypothesizes that mitochondria are the essential component in control of aging. Thus, the dynamic interactions between mitochondrial and glycolytic activity in endothelial cells is essential for maintaining endothelial layer integrity. Our proteomics study indicates that the number of significant mitochondrial proteins in cortical MVs sequentially decreased from young to middle-aged to old mice. Moreover, a significantly higher number of mitochondrial proteins were expressed in young male (~67%) than female (~33%) MVs (Supplementary Table 2). However, this trend reversed in middle-aged mice MVs, and surprisingly, only six mitochondrial proteins were significantly differentially expressed in old male MVs (Supplementary Table 2). Increasing evidence, however, indicates a role for changes in mitochondrial function as a probable central regulator of the aging process. Abnormally rounded mitochondria [109] decreases in mitochondrial number [110] as well as mitochondrial DNA (mtDNA), and copy number decreases [111–113] are significantly linked with aging. We have previously shown that mitochondrial respiration is reduced in old mice [14]. Mitochondrial complex I (MC-I) is thought to be a site of impairment since more subunits are encoded by mitochondrial rather than nuclear DNA. Due to its proximity to ROS produced by mitochondria, mtDNA is considered to be more susceptible to oxidative damage [114–116]. MC-I is often cited as the most likely site of an electron transport chain impairment [114, 117–119]. A human, postmortem study of different brain regions revealed a progressive
age-related decrease in MC-I activity, mainly in the hippocampus and frontal cortex [30]. In nonhuman primates, ATP synthesis capacity and pyruvate dehydrogenase activity were decreased in the putamen of old compared with young animals [120]. In mice [121, 122] and rats [119], the functional impairment of MC-I activity was also evident in the brain of old compared with young animals. A strong positive correlation was demonstrated between decreased MC-I functionality and increased ROS production [119]. Antioxidant defensive failures were coupled with decreases in MC-I, MC-IV, and ATP synthase activity, leading to a reduction in ATP production [123, 124]. Our study supports the concept that aging influences the expression of proteins in MC-I, MC-II, and MC-III (Fig. 4) in mouse cortical MVs. Moreover, the expression of proteins involved in MC-IV and MC-V (ATP synthase) was also significantly decreased in old mice MVs (Fig. 5 and 6).

Basement membrane during aging

The BM, an extracellular matrix, provides additional structural support to the BBB. The BM is composed of collagen, which provides structural integrity and flexibility. Laminin combines with type IV collagen to provide a mesh-like framework for binding other proteins such as nidogen, which stabilize the BM as it binds to and bridges laminin, collagen, and perlecan, as well as provides for charge-dependent filtration and signal transduction. Type IV collagen subunits, classical fibrillar collagens, appear to be the predominant subtype in the MV BM, but the other subtypes are important in providing structural support. BM composition and structure is tissue-specific and dynamic [125] and undergoes compositional and structural changes with aging [126, 127], including the cerebrovascular BM [128]. Our results indicate that considerable rearrangements of the BM, especially in collagen subtypes, occur during aging. For example, the relative abundance of type IV collagen subtypes shows a substantial decrease starting in middle age and continuing in old age, while collagen subtype 1A1, a fibrillar collagen, shows increases with aging. Additionally, BM zone collagens such as collagens XV and XVIII, and FACIT-like/short chain collagens such as collagen 12A1, show increases with aging. Thus, a shift from longer to shorter collagens appears to occur with aging. Collagen 6, another shorter collagen, appears to undergo subunit substitution as collagen 6A1 decreases, while 6A2 increases. A decrease in many but not all of the laminin subtypes and perlecan is consistent with a decrease in collagen 4. We speculate that the BM in old mice is not as tightly woven, is more permeable, and is less flexible than in younger mice MVs.

Blood–brain barrier disruption in the aging brain

BBB breakdown is an emerging biomarker in normal aging [129, 130]. Increases in oxidative stress, and the decreased stability of mRNA and/or proteins, declining ATP production, and changing BM proteins lead to altered BBB integrity in aging brain. Ungvari and colleagues reported that aging aggravated obesity-induced brain microvascular damage and BBB disruption in the mouse hippocampus [131]. In aging, oxidative stress induces cerebral endothelial cells to produce TNF-α that trigger the degradation of the BM, and TJ-proteins, which, in turn, results in BBB disruption and an increase in BBB permeability [132–134]. Inhibition of the glycolytic enzyme, GAPDH, results in higher BBB permeability and barrier dysfunction [103]; the same effect is provoked by overproduction of ROS in endothelial mitochondria [104]. In our discovery-based proteomics study, we also identified that expression of TJ-proteins is significantly decreased in cortical MVs of old mice indicating the probable disruption of BBB in aging brain (unpublished data).

Conclusions

The results of our study support the concept that reduced ROS scavenging ability and mRNA/protein stability are early, precipitating events leading to energy failure and BM disruptions, and which subsequently lead to adverse changes in proteins supporting ATP production by glycolysis and OXPHOS and structural integrity of the BBB-supporting BM. Thus, the results indicate that detrimental effects of normal aging occur as early as 12–14 months in mice and thereby provide support for the view that therapies, especially in vulnerable individuals, should begin in mid-life. While we are not yet able to define with certainty the specific critical events that lead to a compromised and vulnerable brain microvasculature, our
results indicate likely targets for further investigation which we expect will lead to novel therapies to protect not only the microvasculature but also the brain parenchyma.

Acknowledgements We thank Nancy Busija, MA, CCC-SLP, for editing the manuscript. We thank Dana Liu and Barbara Riederreddleman for technical help.

Author contribution P.K.C. and D.W.B. conceived and designed the experiments; R.M. provided mice; P.K.C., S.C., I.R., and J.J.G. performed experiments; P.K.C., and J.J.G analyzed data; P.K.C. interpreted experimental results and prepared figures; P.K.C., and D.W.B. drafted the manuscript; P.K.C., S.C., I.R., J.J.G., P.V.G.K., R.M, and D.W.B. edited and revised the manuscript and approved the final version of the manuscript.

Funding This research was supported in whole or in part by the grants NIH HL-148836 (DWB), NIH AG-063345 (DWB), the Louisiana Board of Regents Endowed Chairs for Eminent Scholars program (DWB), NSF04834 (PVKG), AG074489 (PVKG and RM), NS114286 (PVKG and RM), and AG047296 (RM).

Declarations

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Rosenberg GA. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:1139–51.
2. Brown WR, Moody DM, Thore CR, Challa VR, Anstrom JA. Vascular dementia in leukoaraiosis may be a consequence of capillary loss not only in the lesions, but in normal-appearing white matter and cortex as well. J Neurol Sci. 2007;257:62–6.
3. Bell MA, Ball MJ. Morphometric comparison of hippocampal microvasculature in ageing and demented people: diameters and densities. Acta Neuropathol. 1981;53:299–318.
4. Bell MA, Ball MJ. The correlation of vascular capacity with the parenchymal lesions of Alzheimer’s disease. Can J Neurol Sci. 1986;13:456–61.
5. Bell MA, Ball MJ. Neuritic plaques and vessels of visual cortex in aging and Alzheimer’s dementia. Neurobiol Aging. 1990;11:359–70.
6. Kalaria RN. Cerebral vessels in ageing and Alzheimer’s disease. Pharmacol Ther. 1996;72:193.
7. Ravens JR. Vascular changes in the human senile brain. Adv Neurol. 1978;20:487.
8. Ferszt R, Cervos-Navarro J. Cerebrovascular pathology-aging and brain failure. In: Cervos-Navarro J, Sarkander H, editors. Brain aging: neuropathology and neuropharmacology. New York: Raven Press; 1983. p. 133–51.
9. Cervos-Navarro J, Gertz HJ, Frydl V. Cerebral blood vessel changes in old people. Mech Ageing Dev. 1987;39:223.
10. Moody DM, Santamore WP, Bell MA. Does tortuosity in cerebral arterioles impair down-autoregulation in hypertensives and elderly normotensives? A hypothesis and computer model. Clin Neurosurg. 1991;37:372.
11. Moody DM, Brown WR, Challa VR, Ghazi-Birry HS, Reboussin DM. Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer’s disease. Ann N Y Acad Sci. 1997;826:103–16.
12. Cikic S, Chandra PK, Harman JC, Rutkai I, Katakam PV, Guidry JJ, Giday JM, Busija DW. Sexual differences in mitochondrial and related proteins in rat cerebral microvessels: a proteomic approach. J Cereb Blood Flow Metab. 2021;41:397–412.
13. Chandra PK, Cikic S, Badoo MC, Rutkai I, Guidry JJ, Flemington EK, Katakam PV, Busija DW. Transcriptome analysis reveals sexual disparities in gene expression in rat brain microvessels. J Cereb Blood Flow Metab. 2021;41:2311–28.
14. Sure VN, Sakamuri SSV, Sperling JA, Evans WR, Merdzo I, Mostany R, Murfee WL, Busija DW, Katakam PV. A novel high-throughput assay for respiration in isolated brain microvessels reveals impaired mitochondrial function in the aged mice. Geroscience. 2018;40:365–75.
15. Merdzo I, Rutkai I, Sure VN, McNulty CA, Katakam PV, Busija DW. Impaired mitochondrial respiration in large cerebral arteries of rats with type 2 diabetes. J Vasc Res. 2017;54:1–12.
16. Yue X, Guidry JJ. Differential protein expression profiles of bronchoalveolar lavage fluid following lipopolysaccharide-induced direct and indirect lung injury in mice. Int J Mol Sci. 2019;20:3401.
17. Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, Carter C, Yu BP, Leeuwenburgh C. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev. 2009;8:18–30.
18. Lennicke C, Rahn J, Lichtenhofs R, Wessjohann LA, Seliger B. Hydrogen peroxide - production, fate and role in redox signaling of tumor cells. Cell Commun Signal. 2015;13:39.
19. Han BH, Zhou ML, Johnson AW, Singh I, Liao F, Velimana AK, Nelson JW, Milner E, Cirrito JR, Basak J, Yoo M, Dietrich HH, Holtzman DM, Zipfel GJ. Contribution of reactive oxygen species to cerebral amyloid...
angiomotor dysfunction, and microhemorrhage in aged Tg2576 mice. Proc Natl Acad Sci U S A. 2015;112:E881–90.

20. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000;86:E85–90.

21. Bedard K, Krause KH. The Nox family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313.

22. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension. 2004;44:248–52.

23. Lassegue B, San Martin A, Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res. 2012;110:1364–90.

24. Griendling KK, Sorescu D, Uschio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494–501.

25. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840–4.

26. Krause KH. Aging: a revisited theory based on free radicals generated by NOX family NADPH oxidases. Exp Gerontol. 2007;42:256–62.

27. Hagen TM. Oxidative stress, redox imbalance, and the aging process. Antioxid Redox Signal. 2003;5:503–6.

28. Grimm A, Eckert A. Brain aging and neurodegeneration: from a mitochondrial point of view. J Neurochem. 2017;143:418–31.

29. Mandal PK, Tripathi M, Sugunan S. Brain oxidative stress: detection and mapping of antioxidant marker ‘Glutathione’ in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. Biochem Biophys Res Commun. 2012;417:43–8.

30. Venkateshappaa C, Harish G, Mahadevan A, Srinivas Bharath MM, Shankar SK. Elevated oxidative stress and decreased antioxidant function in the human hippocampus and frontal cortex with increasing age: implications for neurodegeneration in Alzheimer’s disease. Neurochem Res. 2012;37:1601–14.

31. Navarro A, Boveris A. Rat brain and liver mitochondria develop oxidative stress and lose enzymatic activities on aging. Am J Physiol Regul Integr Comp Physiol. 2004;287:R1244–9.

32. Chrissobolis S, Didion SP, Kinzenbaw DA, Schrader LI, Dayal S, Lentz SR, Faraci FM. Glutathione peroxidase-1 plays a major role in protecting against angiotensin II-induced vascular dysfunction. Hypertension. 2008;51:872–7.

33. Forgione MA, Cap A, Liao R, Moldovan NI, Eberhardt RT, Lim CC, Jones J, Goldschmidt-Clermont PJ, Loscalzo J. Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormalities in vascular and cardiac function and structure. Circulation. 2002;106:1154–8.

34. Forgione MA, Weiss N, Heydrick S, Cap A, Klings ES, Bierl C, Eberhardt RT, Farber HW, Loscalzo J. Cellular glutathione peroxidase deficiency and endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2002;282:H1255–61.

35. Taylor JM, Ali U, Iannello RC, Hertzog P, Crack PJ. Diminished Akt phosphorylation in neurons lacking glutathione peroxidase-1 (Gpx1) leads to increased susceptibility to oxidative stress-induced cell death. J Neurochem. 2005;92:283–93.

36. Lee KH, Cha M, Lee BH. Neuroprotective effect of antioxidants in the brain. Int J Mol Sci. 2020;21:7152.

37. Kregel KC, Zhang HJ. An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol. 2007;292:R18-36.

38. Willcox JK, Ash SL, Catignani GL. Antioxidants and prevention of chronic disease. Crit Rev Food Sci Nutr. 2004;44:275–95.

39. Borboli S, Syntichaki P. Cytoplasmic mRNA turnover and ageing. Mech Ageing Dev. 2015;152:32–42.

40. Brewer G. Messenger RNA decay during aging and development. Ageing Res Rev. 2002;1:607–25.

41. Neumann M, Sampathu DM, Kwong LK, Truax AC, Miscenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–3.

42. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsujiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602–11.

43. Inukai S, Slack F. MicroRNAs and the genetic network in aging. J Mol Biol. 2013;425:3601–8.

44. Kour S, Rath PC. Long noncoding RNAs in aging and age-related diseases. Ageing Res Rev. 2016;26:1–21.

45. Grosset C, Chen CY, Xu N, Sonenberg N, Jacquemin-Sablon H, Shyu AB. A mechanism for translationally coupled mRNA turnover: interaction between the poly(A) tail and a c-fos RNA coding determinant via a protein complex. Cell. 2000;103:29–40.

46. Patel GP, Bag J. IMP1 interacts with poly(A)-binding protein (PABP) and the autoregulatory translational control element of PABP-mRNA through the KH III-IV domain. FEBS J. 2006;273:5678–90.

47. Lim J, Ha M, Chang H, Kwon SC, Simanshu DK, Patel DJ, Kim VN. Uridylation by TUT4 and TUT7 marks mRNA for degradation. Cell. 2014;159:1365–76.

48. Jain S, Parker R. The discovery and analysis of P Bod- ies. Adv Exp Med Biol. 2013;768:23–43.

49. Loll-Kriplebeer R, Brown GW. P-body proteins regulate transcriptional rewiring to promote DNA replication stress resistance. Nat Commun. 2017;8:5588.

50. Skourt-Stathaki K, Proudfoot NJ, Gromak N. Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. Mol Cell. 2011;42:794–805.

51. van Hoof A, Staples RR, Baker RE, Parker R. Function of the ski4p (Csl4p) and Ski7p proteins in...
3’-to-5’ degradation of mRNA. Mol Cell Biol. 2000;20:8230–43.

52. Araki Y, Takahashi S, Kobayashi T, Kajihio H, Hoshino S, Katada T. Ski7p G protein interacts with the exosome and the Ski complex for 3’-to-5’ mRNA decay in yeast. EMBO J. 2001;20:4684–93.

53. Seo M, Park S, Nam HG, Lee SJ. RNA helicase SACY-1 is required for longevity caused by various genetic perturbations in Caenorhabditis elegans. Cell Cycle. 2016;15:1821–9.

54. Heintz C, Doktor TK, Lanjuin A, Escoubas C, Zhang Y, Weir HJ, Dutta S, Silva-Garcia CG, Bruun GH, Moranite I, Hoxhaj G, Manning BD, Andrews BS, Mair WB. Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in C elegans. Nature. 2017;541:102–6.

55. Fu XD, Ares M Jr. Context-dependent control of alternative splicing by RNA-binding proteins. Nat Rev Genet. 2014;15:689–701.

56. Southworth LK, Owen AB, Kim SK. Aging mice show a decreasing correlation of gene expression within genetic modules. PLoS Genet. 2009;5:e1000776.

57. Harries LW, Hernandez D, Henley W, Wood AR, Holly AC, Bradley-Smith RM, Yaghoobkar H, Dutta A, Murray A, Frayling TM, Guralnik JM, Bandinelli S, Singleton A, Ferrucci L, Melzer D. Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing. Aging Cell. 2011;10:868–78.

58. Tollervey JR, Wang Z, Hortobágyi T, Witten JT, Zarnack K, Kayikci M, Clark TA, Schweitzer AC, Bradley-Smith RM, Yaghoobkar H, Dutta A, Murray A, Frayling TM, Guralnik JM, Bandinelli S, Singleton A, Ferrucci L, Melzer D. Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing. Aging Cell. 2011;10:868–78.

59. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325:201–4.

60. López-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194–217.

61. Ubaida-Mohien C, Lyashkov A, Gonzalez-Freire M, Tharakan R, Shardell M, Moaddel R, Sembda RD, Chia CW, Gorospe M, Sen R, Ferrucci L. Discovery proteomics in aging human skeletal muscle finds change in spliceosome, immunity, proteostasis and mitochondria. Elife. 2019;8:e49874.

62. Holly AC, Melzer D, Pilling LC, Fellows AC, Tanaka T, Ferrucci L, Harries LW. Changes in splicing factor expression are associated with advancing age in man. Mech Ageing Dev. 2013;134:356–66.

63. Giresi PG, Stevenson EJ, Theilhaber J, Koncarevic A, Parkington J, Fielding RA, Kandarian SC. Identification of a molecular signature of sarcopenia. Physiol Genomics. 2005;21:253–63.

64. Welle S, Brooks AI, Delehanty JM, Needler N, Thornton CA. Gene expression profile of aging in human muscle. Physiol Genomics. 2003;14:149–59.

65. Anisimova AS, Alexandrov AI, Makarova NE, Gladyshev VN, Dmitriev SE. Protein synthesis and quality control in aging. Aging (Albany NY). 2018;10:4269–88.

66. Soti C, Csermely P. Aging and molecular chaperones. Exp Gerontol. 2003;38:1037–40.

67. Winklhofer KR, Tatzelt J, Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 2008;27:336–49.

68. Calderwood SK, Murshid A, Prince T. The shock of aging: molecular chaperones and the heat shock response in longevity and aging—a mini-review. Gerontology. 2009;55:550–8.

69. Sokolov SS, Severin FF. Manipulating cellular energetics to slow aging of tissues and organs. Biochemistry (Mosc.). 2020;85:651–9.

70. Bauerfeind AL, Babitt CC. The appropriation of glucose through primate neurodevelopment. J Hum Evol. 2014;77:132–40.

71. Goyal MS, Hawrylycz M, Miller JA, Snyder AZ, Raichle ME. Aerobic glycolysis in the human brain is associated with development and neotenous gene expression. Cell Metab. 2014;19:49–57.

72. Magistretti PJ. Imaging brain aerobic glycolysis as a marker of synaptic plasticity. Proc Natl Acad Sci U S A. 2016;113:7015–6.

73. Shannon BJ, Vaishnavi SN, Vlassenko AG, Shimony JS, Rutlin J, Raichle ME. Brain aerobic glycolysis and motor adaptation learning. Proc Natl Acad Sci U S A. 2016;113:E3782–91.

74. Epstein T, Xu L, Gillies RJ, Gatenby RA. Separation of metabolic supply and demand: aerobic glycolysis as a normal physiological response to fluctuating energetic demands in the membrane. Cancer Metab. 2014;2:7.

75. Chiarugi A, Dölle C, Felici R, Ziegler M. The NAD metabolome—a key determinant of cancer cell biology. Nat Rev Cancer. 2012;12:741–52.

76. Cerella C, Dickato M, Diederich M. Modulatory roles of glycolytic enzymes in cell death. Biochem Pharmacol. 2014;92:22–30.

77. Eichmann A, Simons M. Need glucose to sprout: local metabolic control of angiogenesis. EMBO Mol Med. 2013;5:1459–61.

78. Bordone MP, Salmon MM, Titus HE, Amini E, Andersen JV, Chakraborti B, Diuba AV, Dubouskaya TG, Ehrke E, Espindola de Freitas A, Braga de Freitas G, Gonçalves RA, Gupta D, Gupta R, Ha SR, Hemming IA, Jaggar M, Jakobsen E, Kumari P, Lakkappa N, Marsh APL, Mitlöhr E, 2016;113:E3782–91.

79.른전은 등, 혈소판에 대한 신경학적 변화와 인간의 뇌. J Neurochem. 2019;151:139–65.

80. CI. The energetic brain - a review from students to students. J Neurochem. 2019;151:139–65.

81. Aldana BI. Microglia-specific metabolic changes in neurodegeneration. J Neurochem. 2019;151:139–65.

82. Bardone LF, Brown A, Swanson RA. Glia in brain energy metabolism: a perspective. Glia. 2018;66:1134–7.

83. Cunnane SC, Trushina E, Morland C, Prigione A, Casa- desus G, Andrews ZB, Beal MF, Bergersen LH, Brinton RD, de la Monte S, Eckert A, Harvey J, Jeggro R, Jhamandas JH, Kann O, la Cour CM, Martin WF, Mitieux G, Moreira PI, Murphy MP, Nave KA, Nuriel T, Oliet SHR, Saudou F, Mattson MP, Sverdlov RH, Millan MJ. Brain energy rescue: an emerging therapeutic concept
for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19:609–33.

82. De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, Quaegebeur A, Ghesquière B, Cauwenberghs S, Eelen G, Phng LK, Betz I, Tembusyer B, Brepoels K, Welti J, Geudens I, Segura I, Cruys B, Bifari F, Decimo I, Blanco R, Wysn S, Van-Gindertael J, Rocha S, Collins RT, Munck S, Daelemans D, Imamura H, Devlieger R, Rider M, Van Veldhoven PP, Schuit F, Bartrons R, Hofkens J, Fraisl P, Telang S, Deberardinis RJ, Schoonjans L, Vinckier S, Chesney J, Gerhardt H, Dewerchin M, Carmeliet P. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 2013;154:651–63.

83. Eelen G, Cruys B, Welti J, De Bock K, Carmeliet P. Control of vessel sprouting by genetic and metabolic determinants. Trends Endocrinol Metab. 2013;24:589–96.

84. Schoors S, Cantelmo AR, Georgiadou M, Stapor P, Wang X, Quaegebeur A, Cauwenberghs S, Wong BW, Bifari F, Decimo I, Schoonjans L, De Bock K, Dewerchin M, Carmeliet P. Incomplete and transitory decrease of glycolysis: a new paradigm for anti-angiogenic therapy? Cell Cycle. 2014;13:16–22.

85. Goveia J, Stapor P, Carmeliet P. Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease. EMBO Mol Med. 2014;6:1105–20.

86. Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol. 2011;37:56–74.

87. Black JE, Polinsky M, Greenough WT. Progressive failure of cerebral angiogenesis supporting neural plasticity in aging rats. Neurobiol Aging. 1989;10:353–8.

88. Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, Magner M, Asahara T, Isner JM. Age-dependent impairment of angiogenesis. Circulation. 1999;99:111–20.

89. Jucker M, Bittig K, Meier-Ruge W. Effects of aging and vincamine derivatives on pericapillary microenvironment: stereological characterization of the cerebral capillary network. Neurobiol Aging. 1990;11:39–46.

90. Shao WH, Li C, Chen L, Qiu X, Zhang W, Huang CX, Xia L, Kong JM, Tang Y. Stereological investigation of age-related changes of the capillaries in white matter. Anat Rec (Hoboken). 2010;293:1400–7.

91. Klein AW, Michel ME. A morphometric study of the neocortex of young adult and old mazedifferentiated rats. Mech Ageing Dev. 1977;6:441–52.

92. Buchweitz-Milton E, Weiss HR. Perfused capillary morphometry in the senescent brain. Neurobiol Aging. 1987;8:271–6.

93. Casey MA, Feldman ML. Aging in the rat medial nucleus of the trapezoid body. III Alterations in capillaries. Neurobiol Aging. 1985;6:39–46.

94. Hinds JW, McNelly NA. Capillaries in aging rat olfactory bulb: a quantitative light and electron microscopic analysis. Neurobiol Aging. 1982;3:197–207.

95. Wilkinson JH, Hopewell JW, Reinhold HS. A quantitative study of age-related changes in the vascular architecture of the rat cerebral cortex. Neuropathol Appl Neurobiol. 1981;7:451–62.

96. Sonntag WE, Lynch CD, Cooney PT, Hutchins PM. Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor 1. Endocrinology. 1997;138:3515–20.

97. Abernethy WB, Bell MA, Morris M, Moody DM. Microvascular density of the human paraventricular nucleus decreases with aging but not hypertension. Exp Neurol. 1993;121:270–4.

98. Goyal MS, Vlassenbroek L, Blazey TM, Su Y, Couture LE, Durbin TJ, Bateman RJ, Benzinger TL, Morris JC, Raichle ME. Loss of brain aerobic glycolysis in normal human aging. Cell Metab. 2017;26:353–360.e3.

99. Moeini M, Lu X, Avti PK, Damseh R, Bélanger S, Picard F, Boas D, Kakkar A, Lesage F. Compromised microvascular oxygen delivery increases brain tissue vulnerability with age. Sci Rep. 2018;8:8219.

100. Noda A, Obha H, Kakiuchi T, Futatsubashi M, Tsukada H, Nishimura S. Age-related changes in cerebral blood flow and glucose metabolism in conscious rhesus monkeys. Brain Res. 2002;936:76–81.

101. Dastur DK. Cerebral blood flow and metabolism in normal human aging, pathological aging, and senile dementia. J Cereb Blood Flow Metab. 1985;5:1–9.

102. Salmina AB, Kuvacheva NV, Morgun AV, Komleva YK, Pozhilenkova EA, Lopatina OL, Gorina YY, Tanurashenko TE, Petrova LL. Glycolysis-mediated control of blood–brain barrier development and function. Int J Biochem Cell Biol. 2015;64:174–84.

103. Hurst RD, Azam S, Hurst A, Clark JB. Nitric-oxide-induced inhibition of glycolaldehyde-3-phosphate dehydrogenase may mediate reduced endothelial cell monolayer integrity in an in vitro model blood–brain barrier. Brain Res. 2001;894:181–8.

104. Alluri H, Stagg HW, Wilson RL, Clayton RP, Sawant DA, Koneru M, Beermann MR, Davis ML, Tharakan A. Reactive oxygen species-caspase-3 relationship in mediating blood–brain barrier endothelial cell hyperpermeability following oxygen-glucose deprivation and reoxygenation. Microcirculation. 2014;21:187–95.

105. Jessen SB, Mathiesen C, Lind BL, Lauritzen M. Interneuron deficit associates attenuated network synchronization to mismatch of energy supply and demand in aging mouse brains. Cereb Cortex. 2017;27:646–59.

106. Klosinski LP, Yao J, Yin F, Fonteh AN, Harrington MG, Christensen TA, Trushina E, Brinton RD. White matter lipids as a ketogenic fuel supply in aging female brain: Implications for Alzheimer’s disease. EBioMedicine. 2015;2:1888–904.

107. de la Torre JC. Are major dementias triggered by poor blood flow to the brain? Theoretical considerations. J Alzheimers Dis. 2017;57:533–71.

108. Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, Harrington MG, Pa J, Law M, Wang DJ, Jacobs RE, Doublai FN, Ramirez J, Black SE, Nedergaard M, Benveniste H, Dighans M, Iadecola C, Love S, Bath PM, Markus HS, Salmon RA, Allan SM, Quinn TJ, Kalaria RN, Werring DJ, Carare RO, Touyz RM, Williams SCR, Moskowitz MA, Katusic ZS, Lutz SE, Lazarov O, Minshall RD, Rehman J, Davis TP, Wellington CL, Gonzalez HM, Yuan C, Lockhart SN, Hughes TM, Chen CLH, Sachdev P, O’Brien JT, Skoog

 Springer
1. Pantoni L, Gustafson DR, Biessels GJ, Wallin A, Smith EE, Mok V, Wong A, Passmore P, Barkof F, Muller M, Breteler MMB, Román GC, Hamel E, Sheshadi S, Gottesman RF, van Buchem MA, Arvanitakis Z, Schneider JA, Drewes LR, Hachinski V, Finch CE, Toga AW, Wardlaw JM, Zlokovic BV. Vascular dysfunction-the disregarded partner of Alzheimer’s disease. Alzheimers Dement. 2019;15:158–67.

109. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A. 1994;91:10771–8.

110. Feher J, Kovacs I, Artico M, Cavallotti C, Papale A, Balacco GC. Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration. Neurobiol Aging. 2006;27:983–93.

111. Short KR, Bigelow ML, Kahl J, Singh R, Coenens-Chimke J, Raghavakaimal S, Nair KS. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A. 2005;102:5618–23.

112. Mengel-From J, Thinggaard M, Dalgaard C, Kyvik KO, Christensen K, Christiansen L. Mitochondrial DNA copy number in peripheral blood cells declines with age and is associated with general health among elderly. Hum Genet. 2014;133:1149–59.

113. Pyle A, Anurgha H, Kurzawa-Akanbi M, Yarnall A, Burn D, Hudson G. Reduced mitochondrial DNA copy number is a biomarker of Parkinson’s disease. Neurobiol Aging. 2016;38:216.e7-216.e10.

114. Ventura B, Genova ML, Bovina C, Formigini G, Lenaz G. Control of oxidative phosphorylation by complex I in rat liver mitochondria: implications for aging. Biochim Biophys Acta. 2002;1553:249–60.

115. Fang EF, Scheibye-Knudsen M, ChuaKF, Mattson MP, Croteau DL, Bohr VA. Nuclear DNA damage signalling to mitochondria in ageing. Nat Rev Mol Cell Biol. 2016;17:308–21.

116. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003;552:335–44.

117. Rygier KA, Grady JP, Turnbull DM. Respiratory chain deficiency in aged spinal motor neurons. Neurobiol Aging. 2014;35:2230–8.

118. Sandhu SK, Kaur G. Mitochondrial electron transport chain complexes in aging rat brain and lymphocytes. Biogerontology. 2003;4:19–29.

119. Petrosillo G, Matera M, Moro N, Ruggiero FM, Paradies G. Mitochondrial complex I dysfunction in rat heart with aging: critical role of reactive oxygen species and cardioprotin. Free Radic Biol Med. 2009;46:88–94.

120. Pandya JD, Grondin R, Yonutas HM, Haghnavaz H, Gash DM, Zhang Z, Sullivan PG. Decreased mitochondrial bioenergetics and calcium buffering capacity in the basal ganglia correlates with motor deficits in a nonhuman primate model of aging. Neurobiol Aging. 2015;36:1903–13.

121. Leuner K, Hauptmann S, Abdel-Kader R, Scherpim I, Keil U, Strosznajder JB, Eckert A, Müller WE. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer’s disease? Antioxid Redox Signal. 2007;9:1659–75.

122. Pollard AK, Craig EL, Chakrabarti L. Mitochondrial complex 1 activity measured by spectrophotometry is reduced across all brain regions in ageing and more specifically in neurodegeneration. PLoS One. 2016;11:e0157405.

123. Xu J, Shi C, Li Q, Wu J, Forster EL, Yew DT. Mitochondrial dysfunction in platelets and hippocampi of senescence-accelerated mice. J Bioenerg Biomembr. 2007;39:195–202.

124. Wang J, Lei H, Hou J, Liu J. Involvement of oxidative stress in SAMP10 mice with age-related neurodegeneration. Neurol Sci. 2015;36:743–50.

125. LeBleu VS, Macdonald B, Kalluri R. Structure and function of basement membranes. Exp Biol Med (Maywood). 2007;232:1121–9.

126. Halfter W, Oettle P, Monnier CA, Camenzind L, Reyes-Lua M, Hu H, Candiello J, Labilloy A, Balasubramani M, Henrich PB, Plodinec M. New concepts in basement membrane biology. FEBS J. 2015;282:4466–79.

127. Caefalan LC, Fertig TE, Gheorghe TC, Hinescu ME, Popescu BO, Pahnke J, Gherghiceanu ME. Age-related ultrastructural changes of the basement membrane in the mouse blood-brain barrier. J Cell Mol Med. 2019;23:819–27.

128. Candiello J, Cole GJ, Half ter W. Age-dependent changes in the structure, composition and biophysical properties of a human basement membrane. Matrix Biol. 2010;29:402–10.

129. Hussain B, Fang C, Chang J. Blood-brain barrier breakdown: an emerging biomarker of cognitive impairment in normal aging and dementia. Front Neurosci. 2021;15:688090.

130. Verheugen ICM, de Jong JJA, van Boxtel MPI, Gron enschild EHBM, Palm WM, Postma AA, Jansen JFA, Verhey FRJ, Backes WH. Increase in blood-brain barrier leakage in healthy, older adults. Geroscience. 2020;42:1183–93.

131. Tucek Z, Toth P, Kosowska D, Gautam T, Mitschelen M, Koller A, Szalai G, Sonntag WE, Ungvari Z, Csizsar A. Obesity in aging exacerbates blood-brain barrier disruption, neuroinflammation, and oxidative stress in the mouse hippocampus: effects on expression of genes involved in beta-amyloid generation and Alzheimer’s disease. J Gerontol A Biol Sci Med Sci. 2014;69:1212–26.

132. Lee P, Kim J, Williams R, Sandhir R, Gregory E, Brooks WM, Berman NE. Effects of aging on blood brain barrier and matrix metalloproteases following controlled cortical impact in mice. Exp Neurol. 2012;234:50–61.

133. Elahy M, Jackaman C, Mamo JC, Lam V, Dhaliwal SS, Giles C, Nelson D, Takechi R. Blood-brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment. Immun Ageing. 2015;12:2.

134. Cai W, Zhang K, Li P, Zhu L, Xu J, Yang B, Hu X, Lu Z, Chen J. Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: an aging effect. Ageing Res Rev. 2017;34:77–87.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.